Recent advances in cancer treatment are transforming outcomes for patients, from Australia's push to eliminate cervical cancer to breakthroughs in blood and bone marrow cancers. CAR T-cell therapy is ...

Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Companies are adopting diverse approaches to reducing unwanted toxicities associated with cell and gene therapy.

Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Cancer incidence is increasing, especially among younger adults, and current risk factors don’t fully account for the trend.

A new study has found that 11 types of cancer are on the rise in the 20 to 49-year-old age group, with obesity emerging as a ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

Oncology pharmacists can operationalize payer-mediated transitions such as biosimilar adoption, minimizing clinician burden while reducing waste and total cost of care. Earlier CAR T-cell therapy ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.